CCTC · Catalyst Crew Technologies Corp.

Catalyst Crew Technologies Corp. executed a series of transactions with its CEO Kevin Rodan Levy to acquire critical intellectual property and establish a Venezuelan subsidiary, positioning the company for expansion in Latin America. The Asset Purchase Agreement dated February 17, 2026, enabled rapid acquisition of proprietary AI healthcare technologies including CardioAI, PulmoAI, and NeuroAI, with patent registrations in Venezuela, closing just days later on February 20. This provided the company immediate access to software, machine learning models, datasets, and related IP essential for its healthcare analytics platform. Subsequently, on March 23, the Share Assignment Agreement transferred 100% ownership of Inversiones Long 33, C.A., transforming it into a wholly-owned subsidiary designated as the operating entity in Venezuela. The final step on April 7 involved assigning the acquired IP to this subsidiary via an Intellectual Property Assignment Agreement, described explicitly as an internal reorganization with no new consideration paid. These moves align the company's structure for regional operations, free of liens or encumbrances per seller warranties, and support broader Latin American strategy. Press releases on key dates publicized these developments and platform introductions, available on public platforms like Yahoo Finance. Investors should note descriptions are qualified by full exhibit texts, with no financial terms like purchase price disclosed.